Ashley McEvoy is recorded as Board Member at Insulet Corp (PODD) since January 1, 2025, CEO at Insulet Corp (PODD), Board Member at PROCTER & GAMBLE Co (PG) since December 12, 2023 and Chairman at PROCTER & GAMBLE Co (PG). The newest filing on record that lists Ashley McEvoy as Chairman at PROCTER & GAMBLE Co (PG) is dated August 23, 2024. PROCTER & GAMBLE Co reported in an 8-K filed October 16, 2025 that Ashley McEvoy was appointed Director, effective October 14, 2025. Insulet Corp reported in an 8-K filed April 28, 2025 that Ashley McEvoy was appointed Class III Director, effective April 28, 2025. Insulet Corp reported in an 8-K filed April 28, 2025 that Ashley McEvoy was appointed President and Chief Executive Officer, effective April 28, 2025. Equibles holds 5 filed executive changes naming Ashley McEvoy; each is listed under recent activity with its source filing. The proxy statement of Insulet Corp reports total compensation of $18,858,968 for Ashley McEvoy in fiscal 2025, including a base salary of $729,808. Ashley McEvoy has spoken on 8 earnings calls and 1 other investor event across 2 companies, most recently for Insulet Corp on September 9, 2026. Those appearances were for Insulet Corp (PODD) and Johnson & Johnson (JNJ). Insulet Corp is classified in the Medical Devices industry within the Healthcare sector. PROCTER & GAMBLE Co is classified in the Household & Personal Products industry within the Consumer Defensive sector. Other companies whose calls Ashley McEvoy spoke on are classified in the Healthcare sector. Other leadership on record at Insulet Corp includes Ashley A. McEvoy (CEO and Board Member), Timothy J. Scannell (Chairman), Flavia H. Pease (CFO) and 7 others.
“Each of the following nominees was elected to serve a one-year term on the Company’s Board of Directors.”
PROCTER & GAMBLE Co Form 8-K, filed October 16, 2025
· Read the filing
“effective on April 28, 2025, the Board appointed Ashley McEvoy as President and Chief Executive Officer of the Company and as a member of the Board as a Class III Director.”
Insulet Corp Form 8-K, filed April 28, 2025
· Read the filing
Ashley McEvoy on recent calls
“Yeah, I mean Larry, first of all, it's great to be here in Boston our hometown Before I get into the timing and the data Let me just first share our perspective on the type 2 market which we see as a tremendous Growth opportunity for Omnipod as well as the aid category.”
“We delivered another quarter of strong revenue growth, expanding profitability, and solid cash flow generation. Our performance reflected the strength of our differentiated business model and our team's dedication to improving the lives of people with diabetes around the world.”
“We're pleased to report a strong start to 2026 with continued growth momentum, robust margin expansion, and discipline execution of the strategic priorities we shared at Investor Day.”
“I'm pleased to share that we close 2025 with another strong quarter, recording our 10th consecutive year of 20% or greater constant currency revenue growth. This consistent track record reflects the strength of our durable recurring revenue profitable business model, and the breadth and depth of our competitive moats.”
“Many of you already know Claire, and we're excited to have such a respected and proven professional in her role. I'd like to welcome Flavia, who is joining us for her first call as Insolid's Chief Financial Officer.”
